Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Total Non-Current Liabilities (2019 - 2021)

Keros Therapeutics filings provide 3 years of Total Non-Current Liabilities readings, the most recent being $12.1 million for Q4 2021.

  • On a quarterly basis, Total Non-Current Liabilities rose 57.66% to $12.1 million in Q4 2021 year-over-year; TTM through Dec 2021 was $12.1 million, a 57.66% increase, with the full-year FY2021 number at $12.1 million, up 57.66% from a year prior.
  • Total Non-Current Liabilities hit $12.1 million in Q4 2021 for Keros Therapeutics, up from $11.5 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $12.1 million in Q4 2021 to a low of $7.4 million in Q3 2020.
  • Median Total Non-Current Liabilities over the past 3 years was $9.3 million (2021), compared with a mean of $9.4 million.
  • Biggest five-year swings in Total Non-Current Liabilities: dropped 25.93% in 2020 and later skyrocketed 57.66% in 2021.
  • Keros Therapeutics' Total Non-Current Liabilities stood at $10.3 million in 2019, then dropped by 25.93% to $7.7 million in 2020, then skyrocketed by 57.66% to $12.1 million in 2021.
  • The last three reported values for Total Non-Current Liabilities were $12.1 million (Q4 2021), $11.5 million (Q3 2021), and $7.8 million (Q2 2021) per Business Quant data.